Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína1. fázis

Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

A legfontosabb adatok

Ki végzi
Innovent Biologics (Suzhou) Co. Ltd.
Hol
Shanghai (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
160 fő, tervezett
Kezdés
2026. ápr. 18.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • placebo
  • Baricitinib tablets
  • IBI3013
A regiszteradat frissítve
2026. április 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for healthy adults in Part 1. Part 2 is for men with active non-segmental vitiligo or severe alopecia areata (patchy hair loss).

Életkor
Part 1 healthy volunteers: 18-45 years. Part 2 vitiligo: 18-65 years. Part 2 alopecia areata: 18-60 years.
Nem
Part 1: men and women. Part 2: men only.
A betegség stádiuma
Vitiligo: non-segmental type, diagnosed ≥3 months and <2 years ago. 3-50% of body skin affected, ≥0.5% of the face, at least 1 active patch. Alopecia areata: SALT ≥50% (AA-IGA grade 3-4), lasting ≥6 months and <4 years, no natural improvement in the past 6 months. Healthy volunteers: weight 50-120 kg (110–265 lb), BMI 17.0-28.0 kg/m2.
Korábbi kezelés
People with alopecia areata who took JAK inhibitor tablets without a good response cannot join. No live vaccines within 30 days before the start.

A részvétel fő kizáró okai

  • Allergy to any part of IBI3013
  • Past shingles, spread-out herpes, or repeated shingles
  • Active tuberculosis now or before, or a positive tuberculosis blood test
  • Pregnant or breastfeeding women
  • Alopecia areata: recent heart attack, stroke, severe heart failure, or past deep vein blood clot

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Part 1 - Healthy trial participants: Understand and voluntarily sign the informed consent form
  • Part 1 - Healthy trial participants: Age between 18-45 years (inclusive), male or female
  • Part 1 - Healthy trial participants: Weight between 50-120 kg (inclusive), and BMI between 17.0-28.0 kg/m2 (inclusive)
  • Part 2 - Active non-segmental vitiligo trial participants: 18-65 years old (inclusive), male
  • Part 2 - Active non-segmental vitiligo trial participants: Diagnosed with non-segmental vitiligo for ≥3 months and <2 years
  • Part 2 - Active non-segmental vitiligo trial participants: Total affected BSA 3-50%, and facial affected BSA ≥ 0.5%; T-VASI 3-50 (inclusive), and F-VASI ≥0.5; ≥1 active lesion
  • Part 2 - : Male participants of reproductive potential agree to use highly effective contraception and avoid sperm donation for 6 months after the last dose
  • Part 2 - Severe alopecia areata trial participants: 18-60 years old (inclusive), male
  • Part 2 - Severe alopecia areata trial participants: Meet the following severe alopecia areata criteria: a) SALT ≥50% (i.e., AA-IGA 3-4 grade) b) No spontaneous remission in the past 6 months (spontaneous remission defined as SALT reduction by ?10 points) c) Current duration of severe alopecia areata ≥6 months and <4 years
  • All participants: Participants of reproductive potential agree to use highly effective contraception and avoid sperm or egg donation for 6 months after the last dose

Ki nem vehet részt

  • All participants: History of live or attenuated live vaccine within 30 days prior to randomization, or expected to receive such vaccines during the study period until 3 months after the last dose of the investigational drug
  • All participants: Donated blood or lost ≥400 mL of blood within 3 months before screening
  • All participants: Received specific treatment within the time frame specified in the protocol, or participated in other investigational drug studies within the specified time
  • All participants: Coexisting diseases at screening or previously, deemed unsuitable for clinical trials
  • Active non-segmental vitiligo/Severe alopecia areata trial participants: Previous or coexisting diseases, which may affect the efficacy or safety evaluation of the study as assessed by the investigator
  • Severe alopecia areata trial participants: Previously received oral JAK inhibitors with poor response; 16. Severe alopecia areata trial participants: Acute myocardial infarction, unstable ischemic heart disease, stroke, chronic heart failure (NYHA class III/IV) within 12 weeks prior to screening; or previous history of deep vein thrombosis, or high risk of deep vein thrombosis as assessed by the investigator; or severe neuropsychiatric disorder, deemed unsuitable for the study by the investigator
  • All participants: Those who are allergic to any component of IBI3013
  • All participants: History of herpes zoster or disseminated herpes simplex (single episode), or recurrent (more than one episode) localized herpes zoster
  • All participants: Known history of active tuberculosis or clinical manifestations suggestive of tuberculosis, or positive interferon-gamma release assay unsuitable for participation
  • All participants: History of drug abuse, drug dependence, or positive drug screening results during the screening period within 12 months
  • Active non-segmental vitiligo trial participants: Coexisting segmental, undetermined type, or mixed-type vitiligo, or other skin pigmentation disorders, or other skin-related abnormalities that may affect the assessment of the study
  • All participants: Abnormal vital signs, serum virology tests, laboratory tests, ECG, or other examinations with clinical significance, and deemed unsuitable for the study by the investigator
  • All participants: Those who cannot tolerate subcutaneous injection
  • All participants: Pregnant or lactating women
  • Severe alopecia areata trial participants: Currently diagnosed with primary diffuse AA or ophiasis AA; or other types of hair loss that may interfere with AA evaluation

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Helyszínek itt: Kína

  • Huashan Hospital, Fudan UniversityShanghai, KínaContact: Jing ZhangRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and severe alopecia areata trial participants. The study is divided into 2 parts, with Part 1 involving healthy trial participants lasting up to 24 weeks, and Part 2 involving active non-segmental vitiligo trial participants and severe alopecia areata trial participants lasting up to 48 weeks.

A vizsgálat 3 csoportja

  • Baricitinib tabletsMár használt kezelés, összehasonlításként

    oral, 2mg, once daily

  • placeboPlacebo, összehasonlításként

    subcutaneous injection/intravenous infusion,single or multiple dosing

  • IBI3013A vizsgált kezelés

    subcutaneous injection/intravenous infusion,single or multiple dosing

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07554222: ki vehet részt
A regiszteradat frissítve
2026. április 28.